Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Jiang



Author of

  • +

    P2.04 - Poster Session with Presenters Present (ID 466)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
    • Presentations: 1
    • +

      P2.04-034 - SPARC/β-Tubulin III Expressions for Clinical Outcomes of ESCC Patients Receiving Nab-Paclitaxel plus DDP Neoadjuvant Chemotherapy (ID 5266)

      14:30 - 14:30  |  Author(s): Y. Jiang

      • Abstract

      Background:
      To assess the role of secreted protein, acidic and rich in cysteine (SPARC) and β-tubulin III (TUBB3) in predicting the clinical outcomes of Chinese ESCC patients receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy.

      Methods:
      The clinical data and tumor biopsies prior treatment from 35 stage II-III ESCC patients receiving nab-paclitaxel plus cisplatin from July 2011 to December 2012 were retrospectively collected and analyzed for SPARC and TUBB3 expressions by immunohistochemistry. The relationships between expressions of SPARC/TUBB3 and response or survival were determined by statistical analysis.

      Results:


      Results:
      All patients received two cycles neoadjuvant CT. 30/35 patients accepted surgery (85.7%). 24/30 patients (80.0%) received adjuvant CT, and 7 patients (23.3%) among them received adjuvant radiotherapy. 30 had R0 resection (100%). Pathological complete response (pCR) was achieved in 4 patients (13.3%). Near pCR (microfoci of tumor cells on the primary tumor without lymph nodal metastases) was acquired in 2 patients (6.7%). Down-staging was observed in 19 of 30 patients (63.3%). SPARC and TUBB3 statuses were evaluated in 22 patients. There was no significant correlation between TUBB3/SPARC status and clinical response .The median PFS in TUBB3 negative staining samples was longer than those in TUBB3 positive staining samples, although there was no statistical difference of OS between two groups. The median PFS/OS in SPARC negative staining samples and SPARC positive staining samples have no statistical difference.

      Results:
      All patients received two cycles neoadjuvant CT. 30/35 patients accepted surgery (85.7%). 24/30 patients (80.0%) received adjuvant CT, and 7 patients (23.3%) among them received adjuvant radiotherapy. 30 had R0 resection (100%). Pathological complete response (pCR) was achieved in 4 patients (13.3%). Near pCR (microfoci of tumor cells on the primary tumor without lymph nodal metastases) was acquired in 2 patients (6.7%). Down-staging was observed in 19 of 30 patients (63.3%). SPARC and TUBB3 statuses were evaluated in 22 patients. There was no significant correlation between TUBB3/SPARC status and clinical response .The median PFS in TUBB3 negative staining samples was longer than those in TUBB3 positive staining samples, although there was no statistical difference of OS between two groups. The median PFS/OS in SPARC negative staining samples and SPARC positive staining samples have no statistical difference.

      Conclusion: